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Abstract
Cardiovascular disease (CVD) is the largest cause of premature death in human populations throughout the world.
Circulating plasma lipid levels, specifically high levels of LDL or low levels of HDL, are predictive of susceptibility to CVD. The
scavenger receptor class B member 1 (SCARB1) is the primary receptor for the selective uptake of HDL cholesterol by liver
and steroidogenic tissues. Hepatic SCARB1 influences plasma HDL-cholesterol levels and is vital for reverse cholesterol
transport. Here we describe the mapping of a novel N-ethyl-N-nitrosourea (ENU) induced point mutation in the Scarb1 gene
identified in a C57BL/6J background. The mutation is located in a highly conserved amino acid in the extracellular loop and
leads to the conversion of an isoleucine to an asparagine (I179N). Homozygous mutant mice express normal Scarb1 mRNA
levels and are fertile. SCARB1 protein levels are markedly reduced in liver (,90%), but not in steroidogenic tissues. This leads
to ,70% increased plasma HDL levels due to reduced HDL cholesteryl ester selective uptake. Pdzk1 knockout mice have
liver-specific reduction of SCARB1 protein as does this mutant; however, in vitro analysis of the mutation indicates that the
regulation of SCARB1 protein in this mutant is independent of PDZK1. This new Scarb1 model may help further our
understanding of post-translational and tissue-specific regulation of SCARB1 that may aid the important clinical goal of
raising functional HDL.
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Introduction
Cardiovascular disease (CVD) is the largest cause of premature
death in human populations throughout the world. It has long
been known that circulating plasma lipid levels, specifically high
levels of LDL or low levels of HDL, are predictive of susceptibility
to CVD. While compounds exist for lowering LDL, approved
treatments for specifically increasing HDL are lacking. The
scavenger receptor class B member 1 (SCARB1, also known as
SR-B1) is a receptor for HDL that mediates the selective uptake of
HDL cholesterol [1] but can also bind to other ligands including
unmodified LDL and VLDL [2–5]. Knockout Scarb1
2/2 mice
have elevated HDL cholesterol levels, reduced selective HDL-
cholesterol clearance, decreased bile cholesterol concentration and
secretion, and thus reduced reverse cholesterol transport (RCT)
[6–10]. In addition, disruption of Scarb1 in chow-fed Apoe-deficient
(Scarb1/Apoe double KO [dKO] mice) or Western diet-fed LDL
receptor-deficient (Scarb1/Ldlr dKO) mice develop markedly
accelerated atherosclerosis [8,11,12], demonstrating that elevated
HDL and its atheroprotective effects are dissociated when reverse
cholesterol transport (RCT) is impaired.
N-ethyl-N-nitrosourea (ENU) has long been known as the most
effective method to introduce heritable mutations in the mouse
[13]. With the completion of the mouse genome, ENU has been
revisited as a viable route in functional genomics with no less than
ten international large-scale ENU screens [14,15]. Using this
approach a mutation identified in a C57BL/6J (B6) screen
performed at The Jackson Laboratory (mutant ID: HLB348) [16]
and selected based on elevated HDL cholesterol was mapped to
the Scarb1 gene and is described here. Homozygous mutant mice
on a ‘pure’ B6 background are fertile and have increased HDL
and decreased selective uptake of cholesteryl ester. Furthermore,
the mutation causes a 90% reduction of SCARB1 protein levels in
the liver but this specific reduction is independent of interactions
with PDZK1, which is also known to reduce SCARB1 protein
levels specifically in the liver.
Results
Identification of the ENU mutant HLB398 and heritability
testing
At 8 weeks of age, while consuming standard laboratory chow, a
male G3 animal, the founder of the mutant strain discussed in this
report, showed an 44% increase in total plasma cholesterol (117
and 168 mg/dL for control and mutant respectively) and a 73%
increase in plasma HDL cholesterol (73 and 133 mg/dL for
control and mutant respectively) which exceed 2.5 standard
PLoS ONE | www.plosone.org 1 August 2009 | Volume 4 | Issue 8 | e6521deviation units from control means. Repeat testing one week later
confirmed these results; therefore the animal was designated
mutant HLB398 and entered heritability testing.
A genome-wide scan of the first 77 backcross animals showed
that the high HDL ENU mutation mapped to Chr 5 (109 Mb to
138 Mb) with a LOD score of 8.6 (Figure 1A). Further mapping,
using a combination of intercrosses between backcross animals and
continued backcrossing of selected recombinants, yielded 334 total
progeny and reduced the genomic location to a 2.1 Mb interval
(LOD = 49.5, D5Mit160 - D5Mit214). This region contains
approximately 20 genes, including an obvious candidate Scarb1
based on its known role in HDL metabolism (Figure 1B). The
inter-crossing of backcross animals clarified that the effect of the
mutation on HDL was additive; female mice had 62, 87, and
142 mg/dL HDL and males were 93, 115 and 177 mg/dL HDL
for wildtype, heterozygous and homozygous mutants respectively
(t-test p,0.001 between all pairs within sex analysis (Figure 1C).
Fertility
In contrast to Scarb1
2/2 mice, homozygous Scarb1
I179N mice
(males and females) had normal fertility. Litter sizes from four
homozygous mutant breeding pairs in the original B6 background
had a mean of 6.9 (+/22.4 SD) progeny per litter from ten litters.
This is not significantly different from control B6 mice (6.6
progeny per litter +/20.9 SD). Approximately 1/30 of pups died
before weaning age.
Mating of heterozygous mutant mice (B6:D2 mixed back-
grounds from the mapping population) yielded homozygous and
heterozygous mice in expected frequencies (Table 1). Data from
24 backcross litters (B6xD2)F1s x D2) segregating at the mutant
locus indicates that heterozygous and homozygous D2 alleles are
Figure 1. Mapping ScarbI
179N. [A] QTL/mutant mapping analysis
(B6-HLB398xD2) for HDL. Dashed line indicates 99% significance
threshold after 1000 permutations. Vertical marks above the x-axis
indicate location of markers, additional markers were added to Chr 5
after initial analysis indicated chromosome 5 as the only significant
locus with B6 alleles giving high HDL levels. [B] Recombinant map
and fine mapping on D2 background. Initial QTL mapping located
the critical region between 109 and 138 Mb (grey region). Further
backcrossing to D2 generated a number of recombinant congenic lines
(A–F) narrowing the region to approximately 2 Mb at 124–126 Mb
(D5Mit60 - D5Mit214). Triangles indicate locations of markers within the
initial fine-mapped region. [C] Distribution of HDL in B6 x D2
mapping population segregating at the Scarb1 locus showing
that the allele effect is additive. HDL mean +/2 SEM given for each
sex separately and N for each genotype-sex group. Genotypes at the Sr-
b1 locus: +/+ indicates mice with no mutant B6 allele, +/ENU indicates
mice with a single mutant B6 allele, and ENU/ENU indicates mice with
two B6 mutant alleles. Within sex analysis reveals a significant difference
between each genotype group (p,0.001).
doi:10.1371/journal.pone.0006521.g001
Table 1. Observed genotypic ratios at the peak marker from
Scarb1
I179N breeding mice.
Scarb1 Genotype
Litters Sex wt/wt Het m/m Total
Backcross M 43 43 NA 86
(B6:D2 F1s) x D2 F 47 35 NA 82
24 90 78 NA 168 Total
Intercross M 8 14 9 31
(B6:D2 F1s) x (B6:
D2 F1s)
F5 1 4 9 2 8
9 13 28 18 59 Total
Homozygous D2 alleles shown by ‘wt/wt’; ‘Het’ indicates a single copy of B6
carrying the ENU mutation and a D2 allele, ‘m/m’ indicates homozygous B6
mutants carrying both mutated alleles. Backcross population: Mice that were
heterozygous for the Scarb1 mutation (B6:D2 derived from the backcross BC1
population) were used for further mapping by backcrossing a second time to
D2 (BC2 giving rise to 24 litters. Genotypes of the progeny are not significantly
different from the expected frequency. Intercross population: Nine litters were
generated by inter-crossing animals that were heterozygous (from the
backcross population BC2) segregating at the Scarb1 mutation. The ratios are
not significantly different from Hardy-Weinberg equilibrium.
doi:10.1371/journal.pone.0006521.t001
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is not significantly different between males and females (p=0.35,
262 contingency Fisher’s exact test). In addition, eight intercross
litters were generated (B6xD2J F1s x B6xD2 F1s) with parents
heterozygous at the mutant locus. The distribution of genotypes in
these litters indicate the overall ratio of homozygous D2,
heterozygous and homozygous mutant alleles were not signifi-
cantly different from the expected Hardy-Weinberg ratio (Chi-
squared test P=0.94).
Gene expression
Given that Scarb1 was an obvious candidate, real-time PCR was
performed using liver tissue to test expression of Scarb1 between
HLB398 mutant mice and B6 controls. However, no significant
difference between the mutant strain relative to control B6 mice
was observed. Additional genes that mapped in the region and
were expressed in the liver according to the SymATLAS database
[17] were tested; Ncor2, Dhx37, Bri3bp, and Aacs; but none showed
significant differential expression between B6 and the mutant
(Figure 2). Thus, we concluded that the causal mutation was
likely a sequence variant that affected the protein code or
translation.
Sequencing and bioinformatics of Scarb1
Sequencing of exons revealed a single point mutation conferring
a T to A transversion in the fourth exon at 536 bp from the ATG
start site causing the 179
th amino acid to change from an
isoleucine (I) to an asparagine (N) (179N). A/TRT/A transver-
sions are the most common type of mutation caused by ENU [14].
Isoleucine 179 is highly conserved in species as distant as Xenopus
(Figure 3A). Although it is possible that a second mutation exists
in the mapped (,2.1 Mb) region causing the observed difference
in HDL, the probability of a second mutation leading to a coding
change is p,0.002 [18–20]. This strain is henceforth designated
Scarb1
I179N.
The change from I to N swaps one of the most hydrophobic
amino acids (I) with one of the most hydrophilic amino acids (N)
(Figure 3B) resulting in potentially dramatic physical changes to
the protein structure. SCARB1 is heavily N-linked glycosylated
[21] and thus the introduction of yet another asparagine at 179N
could introduce such a post-translational modification. However,
due to the lack of a serine or threonine at position 181, N-linked
glycosylation is not expected to occur.
A search for putative functional sites was performed with the
eukaryotic linear motif resource (http://elm.eu.org/) [22]. Using
the native mouse B6 sequence, a total of 113 motifs were identified
in the SCARB1 amino acid sequence. Of these, only three
spanned I179; a forkhead-associated (FHA) Class II domain, a
PDZ Class II and a PDZ Class III domain [23]. The FHA Class II
and the PDZ Class III domains are not disrupted by the I-to-N
change at position 179, but the putative PDZ Class II domain is
disrupted. However internal binding to PDZ motifs are rare and
while the only known protein to bind with SCARB1 is the PDZ
domain containing 1 protein (PDZK1), this protein binds to the C-
terminus of SCARB1 [24].
Western analysis of tissues
Western analysis was performed for SCARB1 in female liver,
ovaries, and adrenals in Scarb1
I179N mice compared with
B6Scarb1
+/+ control mice. In liver, Scarb1
I179N mice had just
11.4% of SCARB1 relative to controls (p=3.2610
26). As
reference and additional controls, Scarb1
2/2 mice, which are on
a mixed B6:129 background, were also compared with control
B6.129Scarb1
+/+ mice. Interestingly, SCARB1 levels in adrenals
and ovaries were unchanged in Scarb1
I179N mice compared to B6
(t-test: adrenals p=0.95 and ovaries p=0.39; Figure 4). Levels of
SCARB1 protein in the ovaries were highly variable for wildtype
and mutant mice, as observed previously [9], probably because
these experiments did not control for the estrus cycle.
Serum lipid and lipoprotein analysis
The plasma lipid profile in homozygous Scarb1
I179N mutant mice
was analyzed and compared with C57BL/6J controls (hence forth
B6Scarb1
+/+)( Table 2). For all lipid measurements; homozygous
Scarb1
I179N mice were significantly higher than control mice
(p,0.01). The relative lipid effects of the Scarb1
I179N mutant
compared to controls are comparable to those of Scarb1
2/2 mice
compared to their controls (Table 2).
FPLC was performed using pooled plasma (N=6) from female
mice and total cholesterol was assayed for the fractions
(Figure 5A). Scarb1
I179N mice had a larger HDL peak. Western
blot analysis showed that apoA-1 signal peaked at the same
location as HDL for the Scarb1
I179N and control mice. Scarb1
I179N
mice show an increase in ApoE in the fractions 22–28. These
fractions are also accompanied by an increase in ApoA1 when
compared to B6 controls and may represent the unusually large
species of HDL seen in Scarb1
2/2 mice (Figure 5B).
HDL turnover and selective uptake of cholesteryl ester
(CE)
Turnover of CE was examined by using double-labeled HDL.
HDL protein was labeled with [
125I]-tyramine cellobiose and
cholesteryl ether with [
3H]. Plasma was monitored after the initial
injection for 24hours, after which mice were euthanized and
selective uptake measured in tissues. Scarb1
I179N mice showed a
reduced clearance rate of CE. In liver tissue, uptake of HDL CE at
24 hours is significantly reduced in mutant Scarb1
I179N mice (50%
reduction, p,0.01), (Figure 6A), while other tissues (adrenals,
kidneys and testis) were unaffected (data not shown). In addition,
selective uptake as measured in plasma was eliminated in
Scarb1
I179N mice (Figure 6B). Thus, the decreased SCARB1
protein levels in the liver of Scarb1
I179N mice cause a reduction in
Figure 2. RT-PCR of Scarb1 and surrounding genes on mouse
Chr 5. Liver tissue examined in mutant Scarb1
I179N and B6 control mice
(N=4). Additional genes that mapped in the region and were expressed
in the liver according to the SymATLAS database [17] were also tested;
Ncor2, Dhx37, Bri3bp, and Aacs; but none showed significant differential
expression between B6 and the mutant. DCt are presented as means
with +/2SEM. Correcting for multiple tests using the Bonferroni
correction requires p,0.007 for significance at a=0.05.
doi:10.1371/journal.pone.0006521.g002
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from plasma and increased HDL cholesterol.
In vitro analysis of Scarb1
I179N
Previous in vitro mutant based analysis of SCARB1 amino acids
identified several residues that affect HDL binding and N-linked
glycosylation sites [21,25,26]. However the only residues exam-
ined that affect protein levels of SCARB1 are those at the C-
terminus that interact with PDZK1. Here, vectors expressing
wildtype Scarb1 and the mutant sequence Scarb1
I179N were co-
transfected with either GFP or Pdzk1 expressing vectors (Figure 7).
Our analysis shows that SCARB1 protein levels are significantly
lower in cells transfected with plasmids coding for the mutant
sequence relative to wild-type sequence (p,0.001), in agreement
with the mutant mouse in vivo data.
PDZK1 is known to interact with and specifically affect SCARB1
protein levels in the liver but not other tissues. Co-expressing a
vector for Pdzk1 in cells with a vector for either the Scarb1 wildtype
or mutant, increased SCARB1 protein levels for both variants.
However, the increase in SCARB1 protein with the mutant plasmid
did not fully restore SCARB1 protein levels to wildtype levels. This
was observed in all three cell types; kidney cells (HEK-293), liver
cells (HuH7), and smooth muscle cells (MOVAS) (data not shown).
Interestingly, in all three cell lines the presence of SCARB1
(wildtype or mutant), significantly increased the amount of
PDZK1 (PDZK1+GFP vs. PDZK1+SCARB1 p,0.001)
(Figure 7A). Transfection efficiencies were determined by GFP
expression and RT-PCR for each gene which was not significantly
different within each experiment. These results suggest that the
I179N mutation causes a liver specific ‘‘knockdown’’ of SCARB1
protein levels that is independent of PDZK1 interaction.
In order to further elucidate the potential mechanism leading to
reduced liver SCARB1 protein levels in the mutant, cells were
treated with chloroquine to inhibit lysosomal degradation, or with
ALLN to inhibit proteosomal degradation. Inhibition of either
degradation pathway fully restored SCARB1 protein levels of the
mutant to those of wildtype levels (Figure 8).
Discussion
This study identified and characterized a mutant mouse strain
with a novel ENU-induced mutation in the Scarb1 gene (I179N).
Figure 3. Bioinformatic characterization of the Scarb1
I179N mutation. Exons were sequenced and one single point mutation in Scarb1 was
identified conferring a T to A transversion in the fourth exon at 536 bp from the ATG start site. This causes the 179
th amino acid to change form an
isoleucine (I) to an asparagine (N) (179N). [A] Conservation: Amino acid sequence for the ENU mutant (Mus_Scarb1
I179N) relative to control un-
mutagenized C57BL/6J mice (Mus_C57BL/6J) and a number of other species illustrating that the mutation is highly conserved. Sequence alignment
was performed using CLUSTALW (www.ebi.ac.uk/clustalw). {Residue number is relative to the mouse sequence. {Myr indicates millions of years since
a shared ancestor with mouse. CLUSTALW Consensus key; * is a single, fully conserved residue, ‘:’ indicates conservation of strong groups, and ‘.’
shows conservation of weak groups. [B] Properties of the amino acids: isoleucine and asparagine are at opposite ends of the hydropathy
spectrum, an index that represents a protein’s hydrophobic or hydrophilic properties. The most hydrophobic amino acids are isoleucine (4.5) and
valine (4.2). The most hydrophilic are arginine (24.5) and lysine (23.9)[53].
doi:10.1371/journal.pone.0006521.g003
Figure 4. Western analysis of SCARB1 protein levels in tissues.
50 ug of total protein loaded (liver, ovary and adrenals in respective
blots) determined by BCA. BACTIN was further used as a loading control.
doi:10.1371/journal.pone.0006521.g004
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in mice with both sexes fertile, in contrast to Scarb1
2/2 female
mice, which are infertile. Scarb1
I179N mice have a pure B6
background and thus the 70% increase in HDL is attributed
wholly to the single amino acid mutation in SCARB1 that causes a
90% decrease in SCARB1 liver protein levels, leading also to a
decrease in selective uptake in livers of mutant mice. Interestingly,
SCARB1 protein levels in other tissues examined were not
affected. As discussed below, these findings could help in the
understanding of SCARB1 protein level regulation. In addition,
the B6 background of Scarb1
I179N could yield subtle importance
differences that have been previously obscured by quantitative
trait loci in other mixed-strain models.
Liver-specific depletion of SCARB1 has previously been
reported in Pdzk1
2/2 mice [27]. Pdzk1
2/2 mice exhibit similar
phenotypes with Scarb1
I179N mutants; SCARB1 protein is reduced
by 95% in liver but is unaffected in the steroidogenic tissues
(adrenals, gonads), HDL cholesterol is elevated by ,1.7-fold, and
FPLC fractionation of Pdzk1
2/2 plasma shows increased levels of
normally sized HDL particles, more closely resembling Scarb1
I179N
profiles shown here rather than Scarb1
2/2 mice [27,28]. It is
therefore possible that the machinery that regulates liver-specific
SCARB1 protein levels in Pdzk1
2/2 mice is also operating in
Scarb1
I179N.
PDZ domains usually bind to the C-terminal 3–6 residues of
interacting proteins [23,29]. PDZK1 has four PDZ domains and it
has been shown that the first PDZ domain (PDZ1) interacts with
the last 3–4 C-terminal amino acids of SCARB1 [30,31].
Nonetheless, although it has been shown that the SCARB1 C-
terminus interacts with PDZ1, the possibility that simultaneous
interactions can occur at other locations has not been eliminated.
Recently it was shown that over-expression of the PDZ1 domain in
Pdzk1
2/2 mice did not affect plasma cholesterol, restored only
,21% of normal SCARB1 protein levels, and the SCARB1 that
was restored was located intracellularly rather than on the cell
surface [28]. The I179N mutation described here does not occur
at the C-terminus; however, PDZ domains do bind to, and interact
with, proteins at internal, that is non C-terminal, sequences
although such internal binding is rare and poorly understood
[23,32–37]. Analysis of PDZ binding motifs revealed a putative
Class II PDZ motif, present in mice and conserved in humans,
which is not present in the mutant Scarb1
I179N due to the highly
hydrophobic isoleucine being replaced by a highly-hydrophilic
asparagine. Because of the similarities of Pdzk1
2/2 to Scarb1
I179N
mice and the questions that remain regarding the PDZK1
regulation of SCARB1, the possibility that the I179N mutation
is somehow involved in this interaction deserves further attention.
To address this possible interaction the I179N mutation was
introduced into vectors for in vitro cell culture analysis. The results,
which are most prominent in HEK293 kidney cells, demonstrate
that the reduction of SCARB1 protein levels is independent of
PDZK1. In the absence of PDZK1, Scarb1
I179N expression results
in less SCARB1 protein relative to wild-type, and over-expressing
PDZK1 does not fully restore mutant SCARB1 protein levels to
wild-type levels.
In order to further elucidate the potential mechanism leading to
reduced liver SCARB1 protein levels in the mutant, cells were
treated with chloroquine to inhibit lysosomal degradation or with
ALLN to inhibit proteosomal degradation. Inhibition of either
Figure 5. Plasma cholesterol analysis for Scarb1
I179N and control
mice. [A] FPLC analysis of plasma lipoproteins: pooled plasma
from female mice (N=6). [B] Western analysis of lipoproteins:
14 ul of respective FPLC fractions and probed for ApoE and ApoAI.
doi:10.1371/journal.pone.0006521.g005
Table 2. Lipid analysis between female Scarb1
2/2, Scarb1
I179N
and control strains.
mean mg/dL SE % change{
HDL Scarb1
I179N 93 2.4 171 ***
B6 Scarb1
+/+ 54 3.2
Scarb1
2/2 159 3.5 201 ***
B6.129 Scarb1
+/+ 79 1.5
Triglycerides Scarb1
I179N 121 5.6 222 **
B6 Scarb1
+/+ 55 2.2
Scarb1
2/2 162 3.4 127 *
B6.129 Scarb1
+/+ 128 4.7
Phospholipid Scarb1
I179N 205 6.6 119 **
B6 Scarb1
+/+ 172 8.2
Scarb1
2/2 242 8.0 129 ***
B6.129 Scarb1
+/+ 187 9.3
Free
Cholesterol
Scarb1
I179N 34 1.3 727 ***
B6 Scarb1
+/+ 51 . 4
Scarb1
2/2 109 1.5 662 ***
B6.129 Scarb1
+/+ 16 2.2
Total
Cholesterol
Scarb1
I179N 119 4.7 175 ***
B6 Scarb1
+/+ 68 4.6
Scarb1
2/2 184 9.1 190 ***
B6.129 Scarb1
+/+ 97 5.2
{% Change indicates change in mutant or KO relative to appropriate control
strain. Significance levels *, **, and *** indicate p,0.05, p,0.01, and p,0.0001
respectively. N=6 animals per group.
doi:10.1371/journal.pone.0006521.t002
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mutant to those of wildtype levels indicating that the1179N
mutant protein is misfolded and degraded. Degradation immedi-
ately after protein synthesis is by the proteosomal route, but
protein that evades this initial degradation is degraded by the
lysosomal pathway after it has reached the plasma membrane.
Further studies are needed to elucidate the details of the
mechanism and to determine why this degradation or potential
differences in turnover are not occurring in other tissues such as
the adrenal.
Strain background of SCARB1 mouse models
It should be noted that HDL and other lipid levels vary greatly
among different wildtype inbred strains [38], and the genetic
determinants of these differences, called quantitative trait loci
(QTL), can be mapped. KO strains on mixed backgrounds such as
B6 and 129 will eventually become fixed at all alleles due to
inbreeding and drift. Control mice with mixed backgrounds will
also become fixed, but for different B6 and 129 alleles than the
KO strain. Consequently QTL will confound the phenotypic
differences between KO and control mice. HDL levels differ
considerably between strains B6 and 129, and these differences are
caused by no less than 20 direct or interacting QTL [39,40]. These
QTL are likely to confound characterization of a target gene.
The commonly used Scarb1
2/2 knock out model (strain:
Scarb1
tm1Kri) [7] was developed using genomic sequence from the
129 strain, and cloned using C57BL/6 (B6) blastocysts. These
mice have been the single largest source to our understanding of
the function of SCARB1 [41]. However, due to infertility of
Scarb1
2/2 females and poor breeding on the B6 background, mice
are maintained on mixed B6:129 backgrounds. Two additional
Scarb1 mouse models have been developed. Scarb1
tm1Dhu, also
described as ‘‘SCARB1 att’’ [9], has a mutation in the promoter
that reduces protein levels of SCARB1 in liver by 53% leading to
an increase in plasma cholesterol of 50–70%. Protein levels are
also reduced in adrenals (83% reduction) and testis. This model
was developed using 129/Sv mouse gene sequence cloned into
BALB/cByJ blastocysts, and are maintained on a mixed
background (129:BALB) [42]. Scarb1
tm1.1Thh, also known as
hypomSCARB1-KO
liver [43], was developed as a liver-conditional
knockout using Cre recombinase loxP technology. Mice were
developed using 129/Sv ES cells cloned into Alb-Cre transgenic
mice having a B6 background (B6.Cg-Tg(Alb-cre)21Mgn/J) and
backcrossed six times to B6. While the intention of this line was to
Figure 6. Selective uptake of cholesteryl ester in plasma and liver. [A] Uptake of [
125I] upper panel and [
3H] lower panel in plasma over 24 hrs
and in tissues: liver, adrenals, testis and kidney at 24 hrs. *Indicates a significant difference (p,0.01) between Scarb1
I179 and control mice in uptake of
[
3H] in liver (means +/2SEM). [B] Uptake in plasma. Data is presented as means +/2SEM. Selective uptake determined from the clearance of double
radio-labeled HDL in plasma over 24 hrs. FCR indicates fractional catabolic rate.
doi:10.1371/journal.pone.0006521.g006
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icantly reduced in all tissues to varying degrees, with complete
knockdown in liver in the presence of Cre recombinase.
As discussed above, a substitute for Scarb1 attenuated models
could be the Pdzk1
2/2 mouse models, since Pdzk1
2/2 mice have a
95% liver specific reduction in SCARB1 protein levels and do not
have fertility abnormalities. Two Pdzk1
2/2 models have been
generated thus far, however one is on a pure 129SvEv genetic
background (Pdzk1
tm1Kr) [27], and a second has a mixed B6:129
background (Pdzk1
tm1Dls) [44]. In addition, PDZK1 is known to
interact with numerous other membrane associated proteins,
including at least one, solute carrier family 22, member 5 (Slc22a5,
also known as Octn2), that affects plasma cholesterol levels [45,46].
The Scarb1
I179N mutant mice provide a model for studying
SCARB1 in a pure B6 background and may help further clarify
differences in phenotypes from Scarb1
2/2 and Pdzk1
2/2 mice.
Furthermore, the I179N mutation may further aid our understand-
ing of SCARB1protein level regulation, trafficking and localization.
Materials and Methods
Mice
C57BL/6J (B6) and DBA/2J (D2) strains were obtained from
The Jackson Laboratory (Bar Harbor, ME) and maintained on a
12 hour light/12 hour dark cycle. Mice were housed in individ-
ually pressurized cages (Thoren Caging Systems, Hazelton, PA),
allowed ad libitum access to acidified water and food. Mice were
weaned onto a standard chow diet based on NIH 31 (LabDiet
5k52, Scott Distributing, Hudson NH). Animal protocols were
reviewed and approved by the respective Institutional Animal
Care & Use Committees at The Jackson Laboratory, and the
University of Pennsylvania.
ENU mutagenesis and heritability testing
As part of a large-scale, high-throughput phenotyping effort at
The Jackson Laboratory, a third-generation ENU mutagenesis
scheme was carried out using B6 as the background strain. This
program has been described elsewhere [16] and further details can
also be found at http://pga.jax.org. Briefly, the third generation
derived from mutagenized mice termed ‘‘G3’’ began a 7-week
phenotyping protocol at six weeks of age, including blood and
plasma analyses, challenge with a high-fat diet [47], evaluation of
body composition, and cardiovascular screens. A mouse with an
HDL level that was two standard deviations above the mean was
selected as a potential mutant and retested. To confirm heritability
Figure 7. In vitro analysis of Scarb1
I179. [A] Co-transfected Scarb1
wildtype and mutant with Pdzk1: Null indicates cells were treated as
with other groups but without plasmid added. PDZK1 primary antibody
in HuH7 cells was diluted 1:5,000 to reduced endogenous detection. All
other conditions are as described in materials and methods. [B] Means
and SE of SCARB1 expression levels from N=3 wells per group of one
experiment, representative of three experiments.
doi:10.1371/journal.pone.0006521.g007
Figure 8. Effects of chloroquine and ALLN on Scarb1 wildtype
and mutant expression. Wild-type (WT), the I179N variant of Scarb1,
and GFP were transiently expressed using HEK293 cells. 36 h post-
transfection, cells were incubated with 675 mM chloroquine (Chlor, to
inhibit lysosomal degradation) or 6100 mM N-acetyl-leucinyl-leucinyl-
norleucinal (ALLN, to inhibit proteosomal degradation) for 6 hr. [A] Cell
samples were collected and SCARB1 proteins were visualized by
immunoblotting. Data are representative of three experiments. [B]
Means and SE of SCARB1 expression levels from N=3 wells per group of
one experiment. Null indicates no plasmids; cells were treated as with
other groups but without plasmid added.
doi:10.1371/journal.pone.0006521.g008
Scarb1
I179N HDL ENU Mutant
PLoS ONE | www.plosone.org 7 August 2009 | Volume 4 | Issue 8 | e6521of the trait, the G3 founder was bred to non-mutagenized B6 mice.
Subsequent F1 progeny were intercrossed and plasma HDL
cholesterol was measured in the F2 progeny under the same
conditions as the founder. The mutant founding line HLB398 has
been designated as Jackson Laboratory stock number JR005495
and is currently available from cryopreserved sperm and embryos.
Live mice are available from the authors.
Mapping
Once the ENU mutant was shown to be heritable, it was
mapped by crossing to the D2 strain. D2 was selected as the
mapping strain because D2 and B6 mice have similar cholesterol
levels on a chow diet (,60 mg/dL) and because two F2
quantitative trait locus (QTL) studies have been performed
between B6xD2 [48,49]. The location of these QTL is informative
for the mapping of the ENU mutation.
A course genome-wide scan, was performed using 50 simple
sequence-length polymorphic markers [50]. This was followed by
additional crosses to generate recombinant mice for Chr 5 which
was saturated with 40 markers.
Phenotyping of mapping population
Blood samples from 8 week old mice fasted for 4 hours in the
morning, were collected in tubes containing EDTA, and
centrifuged at 9,000 rpm for 5 mins. Plasma was frozen at
22uC until analyzed. Plasma samples were thawed, vortexed and
analyzed within a week of being collected. From each plasma
sample concentrations of HDL, total cholesterol (TChol) and
triglycerides (TG) were measured directly using enzymatic
Reagent Kits (#650207, #467825, and #445850 respectively,
Beckman Coulter, Inc., Fullerton, CA) used according to
manufacturer’s recommendations on the Synchron CX Delta
System (Beckman Coulter, Inc).
Gene expression
Gene expression was performed in liver tissue comparing males
from homozygous mutant to control B6 mice (N=4/group).
Expression was performed taking the mean of three technical
replicates for each of four biological replicates, and relative
expression was calculated between target genes and b-actin (DCt).
Tissue collection, RNA extraction, cDNA generation, primer
design and all other details are as described previously [51].
Multiple primer pairs for each gene amplifying 100–150 bp
fragments with primers spanning exons were tested for relative
efficiency using log dilutions of cDNA. Primer pairs were chosen
that amplified equivalently (+/20.25 cycles) over a broad dilution
window typically +/210 fold expression difference, allowing for
100 fold differences (6–7 cycles) to be observed on a linear scale.
PCR products of the final primer pairs chosen for RT-PCR were
sequenced to confirm amplification of the correct genes.
Sequencing of Scarb1
Exons of Scarb1 were sequenced for B6, D2 and the ENU
mutant strain. DNA was prepared from tails using standard
protocols. Cycle sequencing of samples was performed using the
BigDye Terminator kit Version 3.1 (Applied Biosystems, Foster
City, CA). Sequencing reactions were purified using the
XTerminatior kit and run on a 3730xl DNA Analyzer (Applied
Biosystems). Sequencing was performed with 2X coverage for all
exons and 4X coverage for exon-4 where the SNP was identified.
Sequences were analyzed using Sequencher v4.2 (Gene Codes
Corporation, Ann Arbor, MI).
TaqMan SNP assay
A TaqMan SNP assay was developed to distinguish heterozy-
gous from homozygous mutant mice. TaqMan probes; 6FAM:
CCACAGGTTCTCAC (MGBNFQ), VIC: CCACAGGATCT-
CAC (MGBNFQ), Forward primer: TGCTTTTATGAACCG-
CACAGTTG, Reverse primer: GGAGGTACGTGTTGA-
GAAAATGCA. Amplification conditions are as recommended
by Applied Biosystems for SNP genotyping on an ABI 7500-Real-
Time-PCR-System.
Lipid analysis of the homozygous mutant Scarb1
I179N and
control mice
Lipids were analyzed enzymatically using a Cobas Mira-L
analyzer (Roche Diagnostic Systems, Inc.
Indianapolis, IN) using the following assays: total cholesterol
(Infinity Cholesterol assay, Thermo Electron Corporation, Wal-
tham, MA), HDL (EZ-HDL assay, Trinity Biotech, Co Wicklow,
Ireland), and triglycerides (L-Type TG H assay, Wako Pure
Chemical Industries Ltd, Osaka, Japan). Pooled plasma (160 uL)
from female mice (N=6) was analyzed with fast protein liquid
chromatography (FPLC) gel filtration (Amersham Pharmacia
Biotech, Uppsala, Sweden). The cholesterol concentrations in
the FPLC fractions were determined with an enzymatic assay
(Wako Pure Chemical Industries Ltd).
Western analysis
Western analysis was performed on livers, adrenals and ovaries
from the same female mice used for plasma and FPLC analysis
using NuPAGEH 10% Bis-Tris gels (Invitrogen, Carlsbad, CA).
Gels were transferred to nitrocellulose membrane (Invitrogen), and
blots were visualized with the ECL chemiluminescent detection
system (GE Healthcare, Piscataway, NJ). Antibody dilutions were
made 1:5000 (unless otherwise specified) with 5% skim milk.
Plasma FPLC fractions. For each fraction, 14 ul was loaded
per well. APOE and APOA1 primary antibody: rabbit anti-mouse
(Biodesign, Saco, ME), with secondary antibody: HRP goat anti-
mouse IgG (Jackson ImmunoResearch Laboratories, West Grove,
PA).
Tissues. SCARB1 levels were examined in lysates from liver,
adrenals, and ovaries loading 50 ug of total protein determined
using Pierce bicinchoninic acid assay (BCA) Protein Assay Kit
(Thermo Electron Corporation). SCARB1: primary antibody:
rabbit polyclonal to mouse SCARB1 (GeneTex Inc., San Antonio,
TX) with secondary antibody: donkey anti-rabbit IgG ECL
antibody, HRP Conjugated (GE Healthcare). The SCARB1
antibody used was raised to a synthetic peptide (residues 496 to
509: C-SPAAKGTVLQEAKL) which does not include the
mutated amino acid and thus is not expected to influence
detection.
Cell Culture. Cells were scraped off in 1 ml sterile PBS,
vortexed and 500 ul was processed with Trizol for RNA. The
remaining 500 ul of cells was made to 1X loading buffer and 12 ul
total lysate was loaded from each well onto Bis-Tris gels for
Western blot analysis as described above. SCARB1 antibody was
used as above for tissues. PDZK1: primary antibody affinity
purified Sheep Anti-human/mouse-PDZK1 (R&D Systems
Minneapolis, MN) used 1:1,000 with secondary antibody: Anti-
Sheep IgG-HRP (R&D systems) 1:2,000.
In vitro site-directed mutagenesis and cell culture
Mouse Scarb1 (BC004656) and Pdzk1 (BC013512) cones were
obtained in pCMVSport6 vectors (OpenBiosytems - Thermo
Electron Corporation). A control vector for green fluorescent
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Invitrogen. Vectors were cloned and sequenced and the I179N
mutation was introduced into Scarb1 by site directed mutagenesis
using QuikChange Site-Directed Mutagenesis Kit (Agilent Cali-
fornia, USA), by mutating the 536
th base pair from the ATG start
site from a T to A as observed in the Scarb1
I179N mutant mouse.
HEK-293, MOVAS (ATCC Manassas, VA) and HuH7 cells
(Cellbank, Japan) were obtained and maintained as recommended
from the supplier. All cell lines were cultured in Dulbecco’s
modified Eagle medium (DMEM, Invitrogen) containing 10%
fetal bovine serum (Sigma) and 1% antibiotic/antimycotic
(Invitrogen). Media for HuH7 cells also contained 0.2 mg/mL
G418 (Invitrogen). HEK-293 and HuH7 cells were transfected
with Lipofectamine (Invitrogen), while MOVAS cells were
transfected with Lipofectamine 2000 (Invitrogen). Cells were
plated in12-well plates 24 hrs post transfection. Transfections were
performed by co-transfecting an equal amount of plasmid for each
gene in triplicate wells for each experiment. Each experiment was
itself performed in triplicate. Transfections were allowed to
progress for 5 hrs in 500 ul OptiMEM (Invitrogen) then 500 ul
20% FBS DMEM was added to the cells allowing the transfection
to progress to 48 hrs.
HEK293 cells were also used for inhibition of degradation
pathways. Media was replaced at 36 h post-transfection with
media containing either 75 mM chloroquine, 100 mM N-acetyl-
leucinyl-leucinyl-norleucinal (ALLN, Sigma), or PBS (controls).
After the 6 hour incubation with chloroquine or ALLN, cells were
collected and processed as described above Western analysis.
HDL turnover and selective uptake
HDL was double labeled with [
125I] on protein and [
3H] on
cholesteryl ether. HDL was iodinated using a modification of the
method described previously [52] where tyramine cellobiose was
first coupled to HDL prior to iodination. [
125I]-labeled HDL was
subsequently exchange labeled with [
3H]-cholesteryl ether [52].
Both the [
125I]-tyramine cellobiose and cholesteryl ether tracers
are non-hydrolysable and therefore accumulate in tissues following
uptake. Double labeled HDL was injected into the tail veins of
4 hr fasted, 12 wk old male mice. Blood samples were drawn by
retro-orbital bleeding at 2 min, 1 hr, 3 hrs, 6 hrs, 9 hrs, and
24 hrs following injection. Mice were sacrificed at 24 hrs and
tissues (liver, adrenals, kidneys, and testis) were removed for
measurement of tissue uptake.
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